| 摘要 |
<p>The disclosure is directed to the detection, early diagnosis, determination of the severity, and treatment of Alzheimer's disease (AD). A number of biomarkers and combination of biomarkers are disclosed for the determination of AD, including sTNFR2 and Abeta-42; TNFR2 and Ptau-181; sTNFR2, Abeta-42 and PTau-181; and IL-2 and Abeta oligomers. Method of treatment of AD are also disclosed.</p> |
